Tipranavir.
Flexner
Charles
C
Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland 21287-5554, USA. flex@jhmi.edu
Bate
Guy
G
Kirkpatrick
Peter
P
D000284:Administration, Oral; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D011725:Pyridines / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D011753:Pyrones / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D019438:Ritonavir / Q000008:administration & dosage; D013449:Sulfonamides; D013997:Time Factors; D016896:Treatment Outcome
D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D019438:Ritonavir; C107201:tipranavir